It normally takes 17 years for a medical invention to reach its first patient once a scientist had an epiphany.
But occasionally, a thought is so strong and profound that its repercussions are felt far sooner.
This has been the case with CRISPR gene editing, which this month marks its tenth anniversary. It has already significantly influenced laboratory science, enhancing precision and accelerating research, and it has sparked clinical trials for a few malignancies and uncommon disorders.
According to scientists, during the following ten years, CRISPR will provide a number of authorised medicinal therapies and be used to modify crops to increase their productivity and make them more resistant to disease and climate change.
Dr. Eric Topol, a cardiologist who established the Scripps Research Translational Institute and currently serves as its director, described it as "a revolution in process."
Brad Ringeisen, the executive director of the Innovative Genomics Institute at the University of California, Berkeley, noted that the emergence of CRISPR is "unmatched and unequalled" in science. It has altered how we practise biology.
Describe CRISPR.
CRISPR systems are used by bacteria in nature to recognise and neutralise the genes of invading viruses.
This bacterial immune system, also known as "clustered regularly interspaced short palindromic repeats," was discovered to have the potential to modify the cells of people, plants, and animals.
CRISPR can locate a precise location in a DNA strand and cut, add, or swap a genetic "letter" or even a whole word.
Fyodor Urnov, a gene editor at the Innovative Genomics Institute of the University of California Berkeley, remarked, "It's simply fantastic." "Every biological environment that it has been used in has been successful. Imagine a performer that excels in both a symphonic orchestra and a heavy metal band."
The biochemists Jennifer Doudna and Emmanuelle Charpentier published a paper in late June 2012 outlining the mechanism of gene editing via CRISPR. (The two were awarded the chemistry Nobel Prize in 2020 for their discovery.) In January 2013, two additional teams of scientists from Harvard and MIT demonstrated how to use CRISPR to modify mammalian cells.
Professor Doudna of the University of California, Berkeley released a study in the journal Science earlier this month highlighting the advancements CRISPR has made thus far and its continued promise.
In a subsequent email, she stated, "CRISPR has come a long way in just 10 years, farther than I could have expected when our research was initially published. "More clinical trials for CRISPR medicines and novel uses are being seen every year."
Before CRISPR, gene editing was possible, but it wasn't as effective. Compared to older technologies, CRISPR is simple to use, quick, and allows for far greater precision in the alterations, according to multiple specialists.
According to Beverly Davidson, a neurologist at The Children's Hospital of Philadelphia, "there are numerous situations where our lives as scientists would be considerably more difficult without CRISPR."
She claimed that because CRISPR is flexible and precise, many lab procedures are made easier. She can easily train undergraduates in her lab to make CRISPR work.
Even while the likelihood of off-target effects with CRISPR is far lower than with previous editing technologies, it is still possible for it to affect genes inadvertently.
According to Dr. John Leonard, president and CEO of Intellia Therapeutics, which is researching CRISPR-based therapies for cancer and rare disorders, that also explains why the area of gene editing is advancing slowly and methodically. Poor craftsmanship could result in cancer or other issues.
Everyone wants to avoid making mistakes that limit potential because it is so great, according to Leonard.
Treating cancer with CRISPR
By boosting the immune system, CRISPR has the potential to improve cancer treatment.
It has been utilised in blood cancer patient trials since 2016 to alter the patients' own immune cells outside of the body to start an immunological attack on the malignancy.
Multiple forms of blood cancer have been successfully treated using this strategy, known as CAR-T.
Until recently, CAR-Ts had to be manufactured specifically for each patient, which required resources that some patients may not have.
According to Rachel Haurwitz, CEO, president, and co-founder of the company alongside Doudna, Caribou Biosciences is developing on a "off-the-shelf" version of the medication that will be available in a freezer for the following patient who requires it. Weeks of preparation time and possible costs would be reduced in this way.
Six non-Hodgkins lymphoma patients in the therapy's initial clinical study had no sign of the disease after receiving just one dose, according to Haurwitz.
How CRISPR combats uncommon diseases
A single genetic "misspelling" is responsible for more than 6,000 uncommon inherited disorders. For these, CRISPR gives the option of deleting the damaged gene, boosting a different one, or swapping out problematic genetic "letters."
Later this year, the first CRISPR-based gene treatment for sickle cell disease is anticipated to receive approval.
According to Dr. Tippi MacKenzie, a paediatric and foetal surgeon at the University of California San Francisco, "it's tougher to design a single tool to treat all of those variations" with other disorders.
According to MacKenzie, who also serves as the director of the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF, Pompe disease, which weakens the heart and skeletal muscles and can be fatal, has 100 different variations. Each variation would require a different gene edit to be corrected.
Either a gene edit that corrects multiple variants can be found, or quickly developing edits unique to each patient with the condition can be done, according to researchers.
As part of her own research, MacKenzie is creating gene-editing techniques that can be used to a foetus in the late second or third trimester to cure illnesses that are easier to treat in utero but would be harmful if the child were to continue to develop.
By correcting a condition in a foetus, the ailment would not be passed on to any future offspring the child would have.
Prenatal illness treatment has many benefits, according to MacKenzie.
Possibility of crop gene editing
According to Ringeisen, the potential for utilising CRISPR to improve crops is "amazing," and it might help ensure the security of food for billions of people even as climate change increases the risk of more diseases, floods, and droughts.
Despite the fact that most gene-edited crops are still hypothetical, a few have lately entered the market.
According to Zachary Lippman, a plant biologist and geneticist at Cold Spring Harbor Laboratory on Long Island, New York, some of that is technology and some of it is consumer acceptance.
Technically speaking, gene-edited plants might not be considered "genetically changed creatures" in the traditional sense. According to the definition of GMO, it is when genes from one species are transferred to another, such as when a fish gives a plant a new trait.
In contrast, gene editing increases a trait that was previously present in the DNA and genes of a plant or a closely related species, for example, making it more heat- or disease-resistant, quicker growing, or able to be planted more densely. He claimed that these alterations have already been made as a result of breeding or domesticating wild plants, however it is still too early to tell whether the general population will accept them.
The subject of Lippman's own work is tomatoes. He recently used gene editing to make tiny tomato plants from 10 species of tall cherry and grape plants that didn't need staking. He needed three edits, and it took him 18 months to complete them.
It's unclear, according to Lippman, whether businesses will put the time and effort into that kind of work for other crops. A firm that produces soybeans that can withstand drought may be able to increase their prices by 20%, but the new soybean still needs to outperform soybeans bred without CRISPR. Additionally, crops that thrive in one environment probably need different adjustments to thrive in another.
According to Lippman, "at the end of the day, this is not a cure" that will revolutionise food production or help humanity adapt to climate change. This adds even more tool to the arsenal that both traditional and contemporary breeding already possesses.
Challenges over the upcoming ten years
The largest CRISPR controversy began in November 2018, when it was initially claimed that a Chinese scientist named He Jiankui had altered human embryos using the gene editing technique.
The majority of medical ethicists and scientists agree that utilising gene editing to prolong the life of someone suffering from a horrible disease is a good idea. However, they shudder in terror at the thought of altering the human genome in such a way that the change will be passed down down the generations.
Leonard of Intellia Therapeutics stated that "we do not know enough about human biology to undertake genetic engineering changes on behalf of the unborn." Almost all diseases that could be helped by such modification can be treated or avoided in other ways. "Neither can the unborn consent to these operations being performed on them."
He and others argued that while rogue actors may still be engaged in this field, aiming to create "designer babies," mainstream research and business are concentrated on finding solutions to urgent medical and societal issues.
Before CRISPR can be widely used as a medical therapeutic, there are still two significant obstacles to overcome: lowering its exorbitant price and figuring out how to distribute gene modifications to more organs and cells.
Feng Zhang, who contributed to demonstrating the use of CRISPR in mammalian cells, stated that delivery "is the bottleneck that if we can break free, we'll be able to realise a far greater potential of gene editing."
The majority of CRISPR alterations to far have been made in the liver, where many cells end up during the body's cleansing process, the eye, which is relatively simple to target, or the blood, which may be modified outside of the body.
According to Zhang of the Broad Institute of Harvard and MIT, a hub for biomedical research, the fact that even these areas can be accessed is evidence of other scientific breakthroughs and a deeper understanding of the biology of diseases during the past ten years. The body now receives CRISPR inside innocuous viruses or tiny balls of fat, two techniques that have advanced over the past ten years.
Getting big molecules within such small containers is still a challenge. According to Davidson, this makes treating neurological conditions like Huntington's Disease particularly challenging.
"Delivering all of the machinery to the correct cells at the right moment for the right length" is the challenge, according to her.
The cost of CRISPR and other gene editing techniques continues to be a barrier.
One medication for adults with haemophilia, which the FDA approved late last year, costs roughly $3.5 million.
According to Urnov, 300 million individuals worldwide suffer from diseases caused by a single gene, and the great majority don't reside in nations with advanced healthcare systems. "Do we want a world where each of these therapies costs $3 million, and we can figure out right away who can get it and where?"
A single therapy that results in a recovery "may be extraordinarily economically efficient," according to Leonard.
Costs, however, are now only a minor issue because they are predicted to decrease as demand grows and manufacturing and other procedures get better. "We need to start with innovation first, then figure out access," he said.
What else is coming up?
In the future, numerous genes could be successfully edited at once, allowing CRISPR to treat more prevalent, complex disorders.
In a single cell, George Church, who co-authored one of those studies a decade ago, claimed to have already made up to 24,000 modifications and is currently working toward making one million.
With such multiplex gene editing, Church, a geneticist at Harvard Medical School who constantly pushes the boundaries of what is feasible, intends to both help humans develop virus resistance and revive the woolly mammoth.
Ringeisen hopes to be able to manipulate genes that control inflammation in order to potentially treat conditions like Parkinson's and Alzheimer's. In order to trap carbon and stop global warming, he anticipates gene-editing plants and bacteria in agriculture.
Zhang stated that he wanted to employ gene editing to rejuvenate cells and make them healthier and younger. He explained that the objective would be to improve people's health while they are still alive rather than to help them live forever.
And according to Urnov, gene editing will eventually allow us to prevent even complex disorders like heart disease.
In the future, he remarked, "I would love it if we could use CRISPR to stop sickness in its tracks."
Karen Weintraub can be reached at kweintraub@usatoday.com.
A grant from the Masimo Foundation for Ethics, Innovation and Competition in Healthcare helps USA TODAY report on health and patient safety. The Masimo Foundation makes no editorial recommendations.
0 Comments